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Abstract
Background: Nogo-A is a member of the reticulon family of membrane-associated proteins and plays an important
role in axonal remodeling. The present study aimed to investigate alterations in Nogo-A expression following
traumatic brain injury (TBI)-induced inflammation and neuronal damage.
Methods: A weight-drop device was used to deliver a standard traumatic impact to rats. Western blot, RT-PCR and
ELISA were used to analyze the expression of Nogo-A and IL-1β. Nogo-A antisense, and an irrelevant control
oligonucleotide was intracerebroventricularly infused. We also performed H & E staining and luxol fast blue staining
to evaluate the neuronal damage and demyelination resulting from TBI and various treatments.
Results: Based on RT-PCR and western blot analyses, the expression of Nogo-A was found to be significantly
upregulated in the hippocampus beginning eight hours after TBI. In addition, TBI caused an apparent elevation in IL-1β
levels and severe neuronal damage and demyelination in the tested animals. All of the TBI-associated molecular and
cellular consequences could be effectively reversed by treating the animals with the anti-inflammatory drug
indomethacin. More importantly, the TBI-associated stimulation in the levels of both Nogo-A and IL-1β could be
effectively inhibited by a specific Nogo-A antisense oligonucleotide.
Conclusions: Our findings suggest that the suppression of Nogo-A expression appears to be an early response conferred
by indomethacin, which then leads to decreases in the levels of IL-1β and TBI-induced neuron damage.
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Introduction
Traumatic brain injury (TBI) is one of the most prevalent
causes of worldwide mortality and morbidity, and its treat-
ment can result in enormous medical and social expenses
[1,2]. Because of this, the World Health Organization
(WHO) has ranked TBI as a 21st century epidemic with a
severity equivalent to malaria and HIV/AIDS [3]. TBI
causes neurological dysfunction and death through both
primary and secondary cellular mechanisms. One of the
primary effects is TBI-associated damage to axons, blood
vessels, and glial cells in a focal or diffuse pattern. This
damage might subsequently be amplified by certain second-
ary responses including hypoxia, hypotension, ischemia,
edema, and intracranial pressure elevation [4]. Early studies
have shown that the associated alteration in excitatory neu-
rotransmitters, calcium overload, and reactive oxygen spe-
cies (ROS) [5] also contribute to the development of TBI-
induced primary and secondary damage.
The inflammatory response triggered by TBI was demon-
strated to be closely related to TBI-induced neuronal cell
death and functional deficits [6] and is characterized by
glial activation, leukocyte recruitment, and upregulation
of cytokine secretion [7,8]. In the list of the affected
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cytokines, IL-1 appears to be a key mediator of the TBI re-
sponse. In fact, IL-1 has been reported to mediate many
neurological effects in the brain [9]. A relatively high level
of IL-1 has been found to be associated with TBI-induced
neuron loss [7,10,11]. Thus, an efficient method that could
ultimately confer a decline in IL-1 and the traumatic in-
flammatory response is likely to be an attractive strategy
for TBI treatment [12,13].
Nogo-A, a myelin-rich membrane protein of the adult
central nervous system (CNS), is known to act through
specific binding to the Nogo receptor (NgR) [14]. Three
isoforms of the Nogo protein (Nogo-A, Nogo-B, and
Nogo-C) and of the corresponding NgRs have been
identified [15]. The C-terminal sequences of all Nogo
proteins bear a striking homology to several members of
the reticulon or neuroendocrine-specific proteins, suggest-
ing that Nogo-A is a member of the endoplasmic
reticulum-anchored proteins. A growing body of studies
has demonstrated that expression of Nogo-A is not
restricted to neurons and oligodendrocytes in the CNS but
occurs throughout the adult brain and spinal cord [16,17].
It is a potent inhibitor of neurite outgrowth, and it is
known to negatively regulate regeneration in the adult
CNS [18,19]. Treatment with anti-Nogo-A antibodies or
an NgR receptor antagonist can significantly promote
axonal regeneration, neuroanatomical plasticity, and func-
tional recovery [20-22]. Furthermore, recent studies have
also demonstrated that the expression of Nogo-A and
NgRs is stimulated by the activated microglia/macrophages
[23]. This converging evidence points to an important role
for Nogo-A in mediating the inflammatory responses
caused by various neurological conditions including TBI
[24]. As the hippocampus was found to exhibit rather se-
vere neuronal loss after TBI [7,25], in this study, we sought
to investigate TBI-associated hippocampal Nogo-A expres-
sion, cytokine levels, and axonal and neuronal damage. In
addition, we aimed to elucidate the correlation between




Adult male Wistar rats weighing 350 to 400 g were used
in the current study. The rats were purchased from
BioLASCO, Taiwan, Co., Ltd. and housed individually in
hanging wire cages in a temperature-controlled animal
colony at 24°C, with a normal 12-hour/12-hour light/dark
cycle. The animals had free access to food and water, and
they were allowed to acclimate to the light/dark cycle at
room temperature for at least one week before undergoing
the experiments. All animal experiment protocols were
approved by the Animal Care and Use Committee of the
National Chia-Yi University (Approval number: 100010).
As a TBI model, a special weight-drop device which
contained a foam bed on the bottom similar to that
described by Marmarou et al. [26] was used to deliver a
standard traumatic impact to the animals. Each rat was
placed under pentobarbital anesthesia (40 mg/kg, i.p.), a
midline incision was made on the head with a scalpel, and
the skin flaps around the cutting site were peeled off
laterally. After this, a metal helmet was sewn onto the top
of the skull to prevent fracture from the trauma-inducing
impact. Rats were then placed in a prone position on the
bottom plate of the weight-drop device, and a 450-g
weight was allowed to fall freely and vertically from a
height of 1.8 m onto the metal helmet to induce TBI. In
the experiments studying drug effects on the expression of
Nogo-A and traumatic brain injury-associated inflamma-
tion and axonal damage, the rats were injected with
Nogo-A antisense oligonucleotide (5′-TGCTTTCGGTTG
CTG AGGTA-3′) (i.c.v., 5 μl) [27] or indomethacin (i.p.,
2.5 mg/kg, dissolved in 75% alcohol, Sigma, St. Louis,
Missouri, USA) at the time of surgery while anesthetized.
Nogo-A mRNA assay
The relative level of hippocampal Nogo-A transcription
was determined by RT-PCR (n = 4, each group). After
dissection of the brain, total hippocampal RNA was
extracted with Trizol reagent (Gibco BRL, Grand Island,
NY, USA), and 1 μg of each isolated RNA was subjected
to cDNA synthesis. RT for cDNA synthesis was con-
ducted in a 14 μL reaction buffer, containing 1 μL reverse
transcriptase (50 U) and 1 μL oligo(dT)15 primer (50 pmol),
according to the manufacturer’s instructions (Perkin Elmer,
Foster City, CA, USA). The reaction was performed at 42°C
for 30 minutes and subsequently terminated by boiling for
5 minutes. The obtained cDNA was then diluted to 100 μL
with diethylpyrocarbonate (DEPC)-treated H2O, and the
diluents were stored at −20°C prior to use. With the
obtained cDNA (15 μL) as a template, the relative expres-
sion levels of Nogo-A from the animals receiving experi-
mental treatment were determined by PCR. For PCR, a
pair of specific primers, 5′-GCACAGCTTTGCCCATCA-
3′ (forward) and 3′-GGCTTGTGCGACTCGA TCAC-5′
(reverse) (30 cycles), was used to amplify the Nogo-A gene,
and another pair of primers, 5′-TGACGTTGACATCCG
TAAAG-3′ (forward) and 3′-GAGATAGGACCGGAGT
GACA-5′ (reverse) (28 cycles), was designed for the ampli-
fication of actin as an internal control [28]. The final PCR
products were analyzed on an agarose gel, and the relative
intensity was determined using semiquantitative densi-
tometry in conjunction with AlphaEase software (Alpha
Innotech Corp., Miami, FL, USA).
Western blot analysis
The protein samples from various treatments were
resolved by SDS-PAGE. The post-TBI rats (n = 6 in each
group) were decapitated and the brains were removed at
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different time points after TBI. Following the dissection,
the hippocampus was weighed and promptly homogenized
in six volumes (v/w) of ice-cold homogenizing buffer,
which contained 9.91 mM tris-base, 0.32 M sucrose, 1 mM
ethylenediaminetetraacetic acid (EDTA), and proteases
(PMSF: 100 μL/10 ml; leupeptin: 100 μL/10 ml; aprotinin:
100 μL/10 ml). Total proteins were fractionated on an 8%
sodium dodecylsulfate polyacrylamide gel and the resolved
proteins were electrophoretically transferred to a polyvinyli-
dene difluoride (PVDF) membrane. The blotted membrane
was then subjected to antibody detection. Polyclonal anti-
Nogo-A (1:1,000 dilution; R&D System, Minneapolis, MN,
USA) antibodies were used as primary antibodies, which
were then detected by the secondary rabbit anti-goat anti-
body (1:5,000 dilution; Invitrogen, Grand Island, NY, USA)
and visualized by an enhanced chemiluminescence assay
(RPN 2108; Amersham International, Amersham, UK). We
used actin as the internal control (1:5,000 dilution; Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Finally, the
relative protein level of Nogo-A was quantified using semi-
quantitative densitometry equipped with AlphaEase soft-
ware (Alpha Innotech Corp.).
IL-1 detection
In our previous studies [7], we demonstrated that TBI
could induce significant IL-1β overproduction and neuronal
damage in the hippocampus and that the administration of
an IL-1β antagonist could effectively protect animals from
the trauma-associated damage. To elucidate the correlation
between TBI-associated alterations in Nogo-A expression
and the effects of indomethacin on IL-1β production, IL-1β
expression was re-examined in this study by RT-PCR and
ELISA. As in the prior study, the total RNA from the
hippocampus of each rat was isolated for cDNA synthesis,
and the obtained cDNA was used for PCR analysis (n=6 in
each group). The specific primers for IL-1β PCR amplifica-
tion were 5′-ATGGCAACTGTTCCTGAACTCAAC-3′
(forward) and 5′-AGGACAGGTATAGATTCTTTCCTT
T-3′ (reverse)(30 cycles), and the primers for the actin
internal control amplification were 5′-TGACGTTGA
CATCCGTAAAG-3′ (forward) and 5′-ACAGTGAGGC
CAGG ATAGAG-3′ (reverse) (28 cycles) [27]. The subse-
quent analysis procedure assessing the PCR product for
IL-1β expression was similar to that for the Nogo-A deter-
mination. The concentration of IL-1 was also measured
Figure 1 RT-PCR analysis and western blot analysis of Nogo-A mRNA and protein production in the hippocampus after TBI. (A)
The PCR products from Nogo-A transcription after TBI with the yield of actin as an internal control. The sampling times after TBI are
shown on the top (n = 4 in each group). (B) Quantification of Nogo-A mRNA expression by semiquantitative densitometry in conjunction
with AlphaEase software (Alpha Innotech Corp.). (C) Time course of Nogo-A protein production after TBI, internal control: β-actin. Times
shown on top represent hours after injury. (D) Quantification of Nogo-A protein by semiquantitative densitometry in conjunction with
AlphaEase software (Alpha Innotech Corp.). The data are presented as ratios related to the sham group. Bars represent the means ± SEM
values. *p< 0.05 is considered significantly different from sham values using the Mann–Whitney U test. SEM, standard error of the mean;
TBI, traumatic brain injury.
Chao et al. Journal of Neuroinflammation 2012, 9:121 Page 3 of 9
http://www.jneuroinflammation.com/content/9/1/121
using a commercial ELISA kit according to the manufac-
turer’s instructions (Bender Medsystems, San Diego, CA,
USA).
Water content measurement
Rats (n= 4 in each group) were decapitated under deep
anesthesia with 100 mg/kg pentobarbital. The brains were
quickly removed and their wet weights were measured.
The tissue was dried at 120°C for 24 hours. In a double-
blinded manner, the water content was calculated as the
difference between wet and dry weight and expressed as
the percentage of wet weight [25].
Evaluation of neuron damage: H & E staining
Three days post-TBI, each group of rats was sacrificed
using an overdose of pentobarbital (100 mg/kg, i.p.) and
then perfused transcardially with 0.9% NaCl and 10%
formalin. After perfusion, the rats were decapitated and
their brains were removed and embedded in paraffin blocks
(n=5 in each group). Coronal sections (10 μm thickness)
were stained with H & E and subjected to microscopic
examination [7,25].
Evaluation of axonal demyelination: Luxol fast blue
staining
Using a similar procedure to the one described above, the
axonal damage was also analyzed. The embedded coronal
sections (10 μm thickness) were stained with luxol fast blue
(LFB, 0.1%, Sigma) and cresyl echt violet (0.1%, Sigma) for
myelin detection and axonal loss assessment (n=5 in each
group).
Statistical analysis
The obtained data are presented as the means ± standard
error of the mean (SEM). Kruskal-Wallis analyses of
variance (ANOVA) were conducted, and if significant,
were followed by the Mann–Whitney U test. P<0.05
was considered statistically significant.
Results
Upregulation of Nogo-A after TBI
The first experiment conducted in the current study sought
to examine alterations in the expression of Nogo-A in the
hippocampus after TBI. Compared with the sham group,
the Nogo-A mRNA expression level was found to rise
slightly at four hours after TBI induction, but this difference
was not significant (Figure 1A, B). The upregulation of
Nogo-A expression reached a maximum at eight hours
after trauma (approximately four times the maximum level
in the sham group, P<0.05) and lasted for three days. This
stimulatory effect on Nogo-A production was further con-
firmed by protein analysis. Western blot analysis revealed
an increase in Nogo-A protein in the hippocampus four
hours post-TBI. However, a statistically significant elevation
Figure 2 Effects of Nogo-A irrelevant control and antisense oligodeoxynucleotides on hippocampal Nogo-A expression after TBI. (A) RT-PCR
analysis of Nogo-A mRNA transcription level. Actin transcription was used as an internal control. (B) The expression of Nogo-A was quantified by
densitometry and compared with the data from rats injected with saline (sham), which was normalized to 100%. (C) Western blot analysis of Nogo-A
protein level; β-actin was used as an internal control. (D) Quantification of Nogo-A protein by semiquantitative densitometry in conjunction with
AlphaEase software (Alpha Innotech Corp.). The data are presented compared with the sham group. The data are represented as the means±SEM values
(n=6). *p< 0.05 was considered significantly different from the sham value using the Mann-Whiney U test, and #p< 0.05 was considered significantly
different from the TBI with sense values using the Mann-Whiney U test. SEM, standard error of the mean; TBI, traumatic brain injury.
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n the protein level began at eight hours after TBI and lasted
for three days (Figure 1C, D). Moreover, this TBI-induced
stimulation of Nogo-A expression could be reversed by the
administration of Nogo-A antisense oligonucleotide (5′-
TGCTTTCGGTTGCTGAGGTA-3′) immediately after
TBI. As shown in the RT-PCR analysis (Figure 2A and B)
and western blot analysis (Figure 2C and D), microinjection
of Nogo-A antisense oligonucleotide into the lateral
ventricle drastically decreased the TBI-induced Nogo-A
production by approximately 70%. However, the Nogo-A
irrelevant control oligonucleotide (5′-GCAGACCAGC
GCGGA GCT-3′) appeared to be ineffective in decreasing
the TBI-associated Nogo-A production.
Indomethacin attenuated expression of Nogo-A
Indomethacin, a potent non-steroidal anti-inflammatory
drug, was used in this experiment to determine the relation-
ship between TBI-associated inflammatory effects and
Nogo-A expression. The level of Nogo-A was again signifi-
cantly increased as a consequence of TBI, whereas in the
TBI rats that were given indomethacin, Nogo-A expres-
sion at both the mRNA (Figure 3A and B) and protein
(Figure 3C and D) levels returned to those observed in
sham animals. Unlike the direct effect conferred by Nogo-A
antisense oligonucleotide, indomethacin may conceivably
have triggered a novel pathway that resulted in the sup-
pression of Nogo-A expression. However, an interesting
finding was that the administration of indomethacin or
Nogo-A antisense, but not Nogo-A irrelevant control
oligonucleotide, not only suppressed the Nogo-A overpro-
duction but also downregulated the expression of IL-1β
mRNA (Figure 4A and B) and protein (Figure 4C) after
TBI. This strongly suggests that TBI-induced IL-1β pro-
duction is modulated by the level of Nogo-A.
Administration of Nogo-A antisense and indomethacin
protects animals from TBI-induced brain edema, neuronal
damage, and demyelination
In our previous study, we found that TBI induced severe
brain edema. In this study, we attempted to evaluate the
Figure 3 Effects of indomethacin administration on Nogo-A expression. Animals were in one of four groups: sham (no TBI), TBI treatment
(TBI eight hours), TBI combined with vehicle administration (TBI + vehicle), and TBI combined with indomethacin administration
(TBI + indomethacin). (A) RT-PCR analysis of the expression of Nogo-A among different groups along with the analysis of β-actin transcription as
an internal control. (B) Quantification of Nogo-A expression. (C) Western blot analysis of the expression of Nogo-A among different groups along
with the analysis of β-actin as an internal control. (D) Quantification of Nogo-A expression. Bars represent means ± SEM values (n = 5). *P<0.05 is
considered significantly different from the sham value using the Mann–Whitney U test and #P<0.05 is considered significantly different from the
TBI value using the Mann–Whitney U test. SEM, standard error of the mean; TBI, traumatic brain injury.
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effect of Nogo-A antisense and indomethacin on TBI-
induced brain edema formation. TBI-induced neuronal
damage and demyelination were analyzed by H&E and
luxol fast blue staining, respectively. Compared with the
sham group, TBI indeed led to severe brain edema,
neuronal damage, and demyelination, as indicated by
neuronal swelling, shrinkage, and subsequent neuronal
loss (Figures 5, 6A-D). This TBI-associated brain edema
and damage could be effectively diminished by the
administration of Nogo-A antisense oligonucleotide
(Figures 5, 6E and 6F) or indomethacin (Figures 5, 6G and
6H). The results again suggest that the complicated neu-
roprotective mechanism against TBI-induced damage
elicited by indomethacin should be at least in part
mediated by Nogo-A. Additionally, as described above,
the change in the level of IL-1β is modulated by that of
Nogo-A, suggesting that the alteration of Nogo-A expres-
sion might be an early stage event in the protection
process conferred by indomethacin.
Discussion
Our results demonstrate that the production of Nogo-A
mRNA and protein is stimulated several hours after TBI
in the hippocampus, and such TBI-induced upregulation
of Nogo-A can be suppressed by treatment with indo-
methacin. The increase in the levels of IL-1β and the
TBI-associated demyelination and neuronal damage
could also be effectively reversed by this non-steroidal
anti-inflammatory drug. More interestingly, the expression
of Nogo-A was found to be well-correlated with hippocam-
pal IL-1β release, as blockage of Nogo-A by an antisense
oligonucleotide could prevent IL-1β from overloading.
These results suggest that the neuroprotective activity of
indomethacin is mediated by the repression of Nogo-A
expression in the early stages of the process. Subsequently,
the downregulated Nogo-A then promotes a decline in
the release of IL-1β via a pathway that is yet to be
characterized.
Our results on the profile of Nogo-A expression in an
adult rat TBI model are consistent with those observed
in neonatal rat middle cerebral artery occlusion
(MCAO) or pyramidal tract lesion models [29,30], but
differ from previous observations in adult rat MCAO
models [31]. In the neonatal ischemic rats, Nogo-A
expression peaked within 24 hours and returned to near
baseline level by 72 hours [29] whereas in the adult rats,
MCAO caused an alteration in neuronal Nogo-A expres-
sion continuously in the ipsilateral and contralateral
cortex and conferred a global elevation at 28 days after
stroke [31]. As we observed, the expression of Nogo-A
reached a plateau at 8 hours post-TBI and lasted for 72
hours (three days), which is not entirely consistent with
either of the above models. We suspect this may be due
to the differing procedures adopted in brain injury
Figure 4 Effects of TBI, Nogo-A irrelevant control oligonucleotide, Nogo-A antisense oligonucleotide, and indomethacin administration
on the production of IL-1β. All samples were obtained eight hours after TBI. The relative level of the released IL-1β is compared among
different treatment groups: neither TBI nor drug (sham); TBI and Nogo-A irrelevant control oligonucleotide (TBI + Irr), TBI and Nogo-A antisense
oligonucleotide (TBI + Nogo-A antisense); TBI and solvent vehicle (75% alcohol) (TBI + vehicle); and TBI combined with indomethacin injection
(TBI + indomethacin). (A) RT-PCR analysis of the expression of IL-1β among different groups along with the analysis of actin transcription as an
internal control. (B) Quantification of IL-1β expression. (C) ELISA analysis on the expression of IL-1β protein levels among different groups. Bars
represent the means ± SEM values (n = 5). *P<0.05 is considered significantly different from the sham value using the Mann–Whitney U test, and
#P<0.05 is considered significantly different from the TBI-eight hour value using the Mann–Whitney U test. SEM, standard error of the mean; TBI,
traumatic brain injury.
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induction. In our model, the TBI-induced diffused dam-
age may not be restricted to neuronal injury. It might
also cause vessel ruptures and severe damage to the
blood brain barrier (BBB). Consequently, TBI could have
accelerated the recruitment of microglia and macro-
phages, and in turn promptly stimulated earlier Nogo-A
expression. The other possible explanation for the varia-
tions in Nogo-A expression profiles may be the specific
brain area that was subject to investigation in this study.
Based on the results from our previous studies showing
that the hippocampus exhibits rather severe neuronal loss
due to TBI [7,25], it follows that a more rapid TBI re-
sponse, including Nogo-A upregulation, should be more
clearly observed in the hippocampus.
The role of Nogo-A is controversial. Using monoclonal
antibodies (mAbs) to neutralize Nogo-A or using soluble
fragments of NgR to block the Nogo-A-NgR interaction
has been found to increase axonal outgrowth and
sprouting significantly, which correlates with an im-
provement of functional outcome after cerebral ischemia
or stroke [22,32,33]. Neutralization of Nogo-A by mAbs
has also been shown to improve cognitive recovery after
TBI [34]. These studies suggest that Nogo-A elicits the
axonal inhibitory effects after injury and provide a po-
tential treatment strategy for TBI. However, contrary to
the pharmacological results, the genetic deletion of
Nogo-A did not improve functional and histological out-
comes after TBI in aging animals [35]. Compared with
wild littermates, the Nogo-A/B deficient mice showed
diminished recovery from neurological motor deficits
and reduced area and density in the corpus callosum
after TBI [35]. In addition to these interesting results
observed in the Nogo-A/B deficient mice, the NgR defi-
cient mice also display impaired cognitive outcomes in
the Morris water maze task after TBI [36]. It has also been
reported that Nogo-A plays a critical role in stabilizing and
maintaining the architecture of hippocampal pyramidal
neurons [37]. These results suggest that the role of Nogo-A
in TBI-induced neuronal damage is very complex and may
also be age-dependent.
Brain edema is one of the characteristic features observed
in patients suffering from severe traumatic brain injury, and
it can be classified into vasogenic edema and cytotoxic
edema. Vasogenic edema, a secondary response to BBB
compromise following TBI, can lead to a swelling process
Figure 6 Indomethacin and Nogo-A antisense treatment
protects animals from TBI-induced neuronal death and axonal
demyelination. The neurons from animals in different groups: (A, B)
rats without TBI (sham); (C, D) TBI only; (E, F) TBI combined with the
administration of Nogo-A antisense (TBI + Nogo-A antisense); (G, H)
TBI combined with indomethacin administration
(TBI + Indomethacin). The coronal sections (10 μm thickness)
through the hippocampus were stained with either H & E or luxol
fast blue (LFB) for microscopic analysis to determine the neuronal
damage or axonal demyelination, respectively (n = 5 in each group).
TBI, traumatic brain injury.
Figure 5 Effects of indomethacin and Nogo-A antisense
administration on brain edema following traumatic brain injury
(TBI). Animals were divided into five groups: neither TBI nor drug
(sham); TBI and Nogo-A irrelevant control oligonucleotide (TBI + Irr);
TBI and Nogo-A antisense oligonucleotide (TBI + Nogo-A antisense);
TBI and solvent vehicle (75% alcohol) (TBI + vehicle); and TBI
combined with indomethacin injection (TBI + indomethacin). Bars
represent the means ± SEM values (n = 4). *P<0.05 was considered
significantly different from the sham values using the Mann–
Whitney U test; #P<0.05 was considered significantly different from
the TBI values using the Mann–Whitney U test. SEM, standard error
of the mean; TBI, traumatic brain injury.
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and a subsequent rise in intracranial pressure. Cytotoxic
edema causes intracellular fluid accumulation and occurs
during water intoxication and under anoxia-generating
conditions, such as trauma and stroke [25]. Earlier studies
have demonstrated that some neuroprotective agents, such
as tamoxifen, could protect animals from spinal cord
injury-induced edema and neuronal damage via the attenu-
ation of Nogo-A [38]. Some researchers also found that
Nogo-A could also trigger a rapid phosphorylation of the
epidermal growth factor receptor and subsequently activate
a MAPK signaling pathway via the phosphorylation of
MEK and ERK [39]. A similar ERK/MEK/Raf cascade
activation was also observed in our previous studies on
TBI-induced brain edema [25]. The TBI-associated stimula-
tion in Nogo-A might have provided a connection that
correlates the MAPK pathway to the TBI-induced cytotoxic
brain edema. Indomethacin administration significantly
reduced the intracranial pressure [40,41] and BBB disrup-
tion [42], which may attenuate vasogenic brain edema [43].
The protective effect of indomethacin is speculated not
only to reduce the vasogenic edema that results from TBI-
induced intracranial pressure elevation but also to attenuate
cytotoxic edema through the inhibition of the Nogo-A/
MAPK pathway.
A large number of studies have indicated that inflamma-
tion is important to TBI-induced secondary damage to
neurons, glia and myelin [44,45]. TBI induces the rupture
of the BBB and various inflammatory responses, including
cytokine release, the accumulation of leukocytes, and acti-
vation of macrophages and microglia [7,8,46]. Prostan-
glandin E2 (PGE2) is one of the early inflammatory
mediators released by macrophages. Several studies have
demonstrated that PGE2 is significantly elevated in the
plasma of traumatized patients and animals [45,47,48] and
is important for macrophage activation; macrophages may
migrate toward the site of injury, secrete toxic cytokines,
and thereby cause further neuronal damage [44,49].
Indomethacin, a non-specific cyclooxygenase inhibitor,
reduces PGE2 production and elicits a potent anti-
inflammatory effect. In this study, we found that indo-
methacin treatment significantly attenuated the TBI-
induced elevation of hippocampal Nogo-A and IL-1β.
Recent studies have indicated that Nogo-A receptors are
expressed in macrophages in injured peripheral nerves
[23] and in oligodendrocytes of the central nervous system
[19]. It is highly possible that indomethacin blocks PGE2
production, which then attenuates the activation of
macrophage/microglia and further reduces the expression
of Nogo-A and IL-1β release. However, further study is
needed to verify and delineate this complex mechanism.
Conclusions
The results presented here indicate that Nogo-A plays
an important role in TBI-induced IL-1β release and
neuronal and axonal damage. By inhibiting Nogo-A
expression, the systemic delivery of indomethacin can
greatly ameliorate the TBI-induced IL-1β overload and
neuronal damage.
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